Last reviewed · How we verify
UC-MSC infusion
At a glance
| Generic name | UC-MSC infusion |
|---|---|
| Sponsor | Asia Stem Cell Regenerative Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS). (PHASE3)
- Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment (PHASE1)
- Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient (NA)
- Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA (PHASE1, PHASE2)
- Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients (PHASE2)
- Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells (PHASE2)
- Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants (PHASE2)
- Stem Cell Infusion in the Treatment of Patients with Neurological Sequelae After Ischemic Stroke (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |